Head to Head Contrast: ImageneBio (NASDAQ:IMA) vs. Stoke Therapeutics (NASDAQ:STOK)
by Mitch Edgeman · The Markets DailyStoke Therapeutics (NASDAQ:STOK – Get Free Report) and ImageneBio (NASDAQ:IMA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Risk & Volatility
Stoke Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
Profitability
This table compares Stoke Therapeutics and ImageneBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stoke Therapeutics | -753.60% | -59.36% | -51.46% |
| ImageneBio | N/A | -38.99% | -34.84% |
Insider and Institutional Ownership
75.0% of ImageneBio shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Stoke Therapeutics and ImageneBio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stoke Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
| ImageneBio | 2 | 0 | 1 | 0 | 1.67 |
Stoke Therapeutics currently has a consensus price target of $44.25, suggesting a potential upside of 73.80%. ImageneBio has a consensus price target of $28.00, suggesting a potential upside of 591.36%. Given ImageneBio’s higher possible upside, analysts plainly believe ImageneBio is more favorable than Stoke Therapeutics.
Earnings and Valuation
This table compares Stoke Therapeutics and ImageneBio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stoke Therapeutics | $27.59 million | 59.55 | -$6.89 million | ($3.34) | -7.62 |
| ImageneBio | $800,000.00 | 57.46 | -$45.35 million | ($4.58) | -0.88 |
Stoke Therapeutics has higher revenue and earnings than ImageneBio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.
Summary
Stoke Therapeutics beats ImageneBio on 8 of the 14 factors compared between the two stocks.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
About ImageneBio
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.